Pharmaceutical Industry discussion, review, analysis, news and information.

The U.S. FDA has granted orphan drug designation to Agennix's oral formulation of Talactoferrin Alfa (talactoferrin or TLF), curently on Phase II clinical development for the treatment of renal cell carcinoma (RCC).

Talactoferrin Alfa is a unique recombinant form of human lactoferrin, an immunomodulatory protein. Talactoferrin acts by binding to specific receptors found on target cells and inducing the production of key immunomodulatory cytokines and chemokines.

Results from a multi-center Phase 2 RCC trial that included six leading U.S. cancer centers presented at the 2006 Annual meeting of the American Society of Clinical Oncology (ASCO), showed that talactoferrin in RCC are promising.

Source: Agennix